EU completes Meridia review
Executive Summary
EU Committee for Proprietary Medicinal Products "issued a positive opinion reaffirming the favorable risk/benefit profile of sibutramine," Abbott announces June 27. The committee reviewed the obesity drug (Meridia in the U.S.) at the request of Italian Health Ministry after the agency suspended approval of sibutramine. Abbott expects FDA to respond by the fall to a petition from Public Citizen's Health Research Group asking that Meridia be withdrawn (1"The Pink Sheet" June 17, p. 16)...